Applied regardless of the meal, both as monotherapy and in combination with other antihypertensive agents.
The recommended starting dose is 150 mg masteron steroid 1 time per day. The development of the antihypertensive effect is observed after 2 weeks after initiation of therapy at a dose of 150 mg 1 time per day.When there is insufficient control of blood pressure drug dose can be increased to 300 mg 1 time per day.
Use in patients older than 65 years
In patients older than 65 years of correction dose is not required
Use in children and adolescents under the age of 18 years
Since Rasileza safety and efficacy in children and adolescents (under 18 years) has not been established, the drug is not recommended in these patients.
Use in patients with impaired renal or hepatic function
In patients with impaired renal function (glomerular filtration rate at 30 mL / min) and liver (5-9 points on a scale Child-Pyuga) from mild to severe correction dose is not required.
Side effects The safety of Rasileza evaluated more than 7800 patients. The frequency of adverse events (AEs) was not associated with gender, age, body mass index, or race.
In applying the drug at a dose of 300 mg total incidence of AEs was similar to that with placebo. Adverse events were generally moderately expressed, they were temporary and rarely require discontinuation of therapy drug. Most often when applying patients had diarrhea.
In applying the drug were observed increase in the incidence of “dry” cough, typical inhibitors. The incidence of “dry” cough during treatment Rasilezom (0.9%) was similar to that with placebo (0.6%).
In clinical trials in a group Rasileza incidence of angioedema was similar to that in the placebo or hydrochlorothiazide group.
On the part of the digestive tract: often – diarrhea.
Dermatological reactions: sometimes – skin rash.
Changes in laboratory parameters
When using Rasileza rarely observed clinically significant changes in routine laboratory parameters.
Against the background of monotherapy there was a slight decrease in hemoglobin concentration and hematocrit (mean 0.05 mmol / l and 0.16%, respectively), did not require discontinuation of treatment.Reducing the concentration of hemoglobin and hematocrit is also seen with other drugs affecting RAAS in particular ACE inhibitors and angiotensin II receptor antagonists.
When applying in patients with essential hypertension, in rare cases, it showed a slight increase in the potassium concentration of serum (0.9% versus 0.6% for placebo).
In drug therapy in patients with clinically significant changes AG total cholesterol, high density lipoproteins and triglycerides, uric acid or glucose masteron steroid was observed.